The only approved gene therapy for RP today targets a single gene RPE65, which accounts for just 1% to 2% of the total RP patient population. We believe OCU400 has significantly wider commercial ...
AI is impacting customers, workers, firms, and industries ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果